Tango Therapeutics (TNGX) Accumulated Expenses: 2020-2025
Historic Accumulated Expenses for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to $13.1 million.
- Tango Therapeutics' Accumulated Expenses fell 12.61% to $13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.1 million, marking a year-over-year decrease of 12.61%. This contributed to the annual value of $16.5 million for FY2024, which is 7.12% up from last year.
- Per Tango Therapeutics' latest filing, its Accumulated Expenses stood at $13.1 million for Q3 2025, which was up 13.93% from $11.5 million recorded in Q2 2025.
- Tango Therapeutics' Accumulated Expenses' 5-year high stood at $17.5 million during Q4 2022, with a 5-year trough of $202,089 in Q1 2021.
- In the last 3 years, Tango Therapeutics' Accumulated Expenses had a median value of $13.2 million in 2023 and averaged $13.4 million.
- As far as peak fluctuations go, Tango Therapeutics' Accumulated Expenses skyrocketed by 13,312.37% in 2021, and later plummeted by 31.38% in 2025.
- Tango Therapeutics' Accumulated Expenses (Quarterly) stood at $9.9 million in 2021, then soared by 76.95% to $17.5 million in 2022, then declined by 11.97% to $15.4 million in 2023, then climbed by 7.12% to $16.5 million in 2024, then decreased by 12.61% to $13.1 million in 2025.
- Its Accumulated Expenses was $13.1 million in Q3 2025, compared to $11.5 million in Q2 2025 and $10.4 million in Q1 2025.